Clinical Trial Supplies Market Size, Share, Growth Report 2032

Industry Prospective:

The Clinical Trial Supplies Market was worth around USD 1,873.2 million in 2021 and is estimated to grow to about USD 3,022.4 million by 2028, with a compound annual growth rate (CAGR) of approximately 8.3 percent over the forecast period. The report analyzes the Clinical Trial Supplies Market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Clinical Trial Supplies Market.

Request Free Sample

Clinical Trial Supplies Market: Overview

Clinical trial supplies cover a wide range of tools and equipment used in scientific tests, investigations, and clinical research. The increasing R&D spending in pharmaceutical and biopharmaceutical firms, as well as the expanding number of clinical trials done internationally, are driving market expansion. One of the primary factors driving the market's growth is significant growth in the biopharmaceutical industry. Clinical trials are gaining a lot of traction in the fight against diseases like HIV and cancer, as well as the creation of new medication delivery methods. Additionally, the growing tendency of contract research organizations (CROs) is favorably boosting the market growth. Furthermore, technological advancements that aid in the development of cold chain logistics and monitoring technologies are important growth drivers. Pharmaceutical, biotechnological, and medical instrument producers can outsource research efforts to CROs on a contractual basis, allowing them to use more trial materials. Moreover, extensive research and development (R&D) by both governmental and non-governmental organizations (NGOs) for the development of new pharmaceuticals and treatment procedures is predicted to boost the market's prospects.

Covid-19 Impact

The pandemic of Covid-19 has had a beneficial impact on the market's growth. Not only are vaccinations being tested in clinical trials, but also drugs to treat COVID-19 and its symptoms. This will be a significant driver in the clinical trial business. Due to the COVID-19 issue, the clinical trial supply business has seen rapid expansion. The quest for a coronavirus vaccine has sparked a surge in clinical trials around the world. Millions of people must be vaccinated over the world, but first, trials must be completed. As a result of this predicament, clinical trial supply trends have improved.

COVID-19 has pushed the introduction of new models to the market in order to ease the crisis and keep up with shifting trends. Virtual trials, which have been an underpinning technology, are gradually gaining traction and are projected to see significant expansion in the future years. As a result, virtual trials are gradually being embraced to prevent such circumstances, allowing for the deployment of innovative ways to trials and ensuring a better patient experience.

Request Free Sample

Clinical Trial Supplies Market: Driver

Pharmaceutical and biopharmaceutical businesses are increasing their R&D spending.

The pharmaceutical and biopharmaceutical industries are among the world's largest R&D spenders. Pharmaceutical and biopharmaceutical companies have increased their R&D spending significantly in the recent decade. The number of clinical trials conducted throughout the world is expected to rise as a result of this. Market players are actively seeking to assist in R&D initiatives. Increased R&D investment in the next years will significantly boost drug research and development activities, boosting demand for clinical trial supplies.

Clinical Trial Supplies Market: Restraint

Drug development is expensive.

Due to the high attrition rate of drug candidates in development, drug research and development have substantial expenses. Drug R&D processes can fail because R&D for some rare diseases is difficult and requires a specific group of people to undertake a clinical trial. Only 7 out of 100 cancer treatments that make it to the clinical testing stage are approved by the FDA; the majority of drugs fail long before they reach this stage. Developing a new treatment takes 10–15 years and costs USD 2.6 billion on average, from drug discovery to FDA approval. The FDA approves just about 12% of candidates who progress to Phase I clinical trials. This is a major stumbling block to the industry's expansion.

Clinical Trial Supplies Market: Opportunity

R&D investments provide considerable market prospects.

In terms of trial expenses and patient pools, North America and Europe, which have traditionally been the key hubs for clinical trials, are confronting challenges. Recent health changes in the United States, the patent expiration of blockbuster drugs, and the global economic slump have all had an influence on pharmaceutical company profits. As a result, a number of pharmaceutical companies are looking for chances in emerging APAC markets like India, Singapore, South Korea, and China, which offer advantages including cheaper prices and easier access to a diversified patient population. Collaborations or expansions between firms in this sector suggest that they are going towards emerging markets to assist their clients in minimizing the overall time spent in clinical trials, hence lowering their overall cost and allowing for a faster launch of products on the market (post regulatory clearance). CROs can take advantage of these opportunities by assisting pharmaceutical companies in meeting their clinical trial supply demands.

Clinical Trial Supplies Market: Segmentation

The Clinical Trial Supplies Market is segregated based on Services, phase, type, therapeutic area, and end-user.

By Services, the market is classified into Logistics & Distribution, Storage & retention, Packaging, labeling, and blinding, Manufacturing, Comparator sourcing, and Other services (solutions, ancillary supply). The supply chain management sector dominated the market, accounting for the largest share of the market's revenue. Life science firms and contract research organizations (CROs) are likely to increase their demand for supply chain management systems as clinical trials become more global and the number of clinical sites grows. Mobile and supply chain management technology use is likely to be the segment's driving force.

By Phase, the market is classified into Phase 1, Phase 2, Phase 3, Phase 4, and BA/ BE studies. During the projection period, phase III clinical trials are expected to dominate the market. Clinical studies in Phase III are more complicated than those in the previous rounds. Despite the fact that the number of medications in this phase is relatively limited, the level of complexity associated with it is the largest. This phase has the highest failure rate because the sample size and study design necessitate sophisticated dosing at an optimal level. Human and financial losses are associated with failures, and the majority of failures are caused by non-compliance with safety and efficacy requirements. Such a scenario is likely to increase demand for efficient supply chains and logistics, which would have a favorable impact on market growth.

By therapeutic area, the market is classified into Oncology, CNS and mental disorders, Cardiovascular diseases, Digestive disorders, Infectious diseases, Metabolic disorders, Immunology, Blood disorders, and Other therapeutic areas (respiratory disorders, dermatological disorders, rare diseases, ENT diseases, Nephrology). Due to the huge and growing number of research studies on cancer treatments and the growing number of firms working on bringing novel cancer medications to market, oncology is the largest segment in this market. Due to the high incidence and prevalence of cancer, healthcare systems all over the world are working on lowering the disease's burden by implementing novel diagnostic and therapeutic procedures. Effective medications could see widespread adoption in large markets including the United States, Europe, and the Asia Pacific in this scenario. Many pharmaceutical companies are investing heavily in the development of novel cancer treatments in light of these factors.

Report Scope:

Recent Developments

• In 2021, PPD, Inc. is now owned by Thermo Fisher Scientific. With the addition of PPD, Thermo Fisher will be able to provide a full range of world-class clinical development services, from scientific discovery to analyzing safety, efficacy, and healthcare outcomes, to managing clinical trial logistics, to drug development and manufacturing.

Regional Landscape

In terms of market share and revenue, North America dominates the clinical trial supplies market, and this dominance will continue during the projected period. This is owing to the region's large number of essential companies and well-developed healthcare infrastructure. Pharmaceutical and biopharmaceutical businesses' increased spending on R&D is the primary drivers of North America's clinical trial supplies market share. The expanding number of healthcare companies conducting clinical trials in the region, supportive government laws, and the availability of cost-effective goods are all contributing to this expansion.

The Asia Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period, due to a bigger patient pool, more healthcare expenditure, and increased government assistance. Furthermore, large pharmaceutical companies are outsourcing their drug development services to countries like China, Singapore, Malaysia, and India, which is fueling the region's clinical trial supplies industry. This region's quick expansion can be ascribed to rising chronic disease prevalence, lower clinical trial costs compared to the western region, and increased government initiatives to perform clinical trials. Clinical material and supply end-users are also projected to enhance their local presence in these markets due to the strict requirements for importing clinical supplies.

Competitive Landscape

Some of the main competitors dominating the Clinical Trial Supplies Market include - Thermo Fisher (US), Catalent, Inc. (US), Parexel (US), Eurofins (France) UDG Healthcare (Ireland), Piramal Pharma Solutions (India), Almac Group (UK), PCI Pharma Services (US), PRA Health Sciences (US), Biocair (UK), Eurofins (France), Marken (US), Infosys (India), Liveo Research (India), Capsugel (a Lonza Group company) (Switzerland), SIRO Clinpharm (India), KLIFO A/S (Denmark), Clinigen (UK), Ancillare (US), N-SIDE (Belgium), ADAllen (UK), Rubicon (India), Durbin (UK), Recipharm (Sweden), Seveillar (India), Myonex (India)

Clinical Trial Supplies Market is segmented as follows:

By Services

• Logistics & distribution
• Storage & retention
• Packaging, labeling, and blinding
• Manufacturing
• Comparator sourcing
• Other services (solutions, ancillary supply)

By Phase

• Phase 1
• Phase 2
• Phase 3
• Phase 4
• BA/ BE studies

By Type

• Small molecules
• Biologic drugs
• Medical devices

By Therapeutic Area

• Oncology
• CNS and mental disorders
• Cardiovascular diseases
• Digestive disorders
• Infectious diseases
• Metabolic disorders
• Immunology
• Blood disorders
• Other therapeutic areas (respiratory disorders, dermatological disorders, rare diseases, ENT diseases, Nephrology)

By End-User

• Pharmaceutical & Biotechnology companies
• Contract Research Organisations (CROs)
• Medical Devices Companies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa